Article Text

Download PDFPDF
Sentinel node mapping decreases the risk of failed detection of isolated positive para-aortic lymph node in endometrial cancer
  1. Jacqueline Nunes Menezes1,
  2. Bruna Tirapelli Gonçalves1,
  3. Carlos Chaves Faloppa1,
  4. Lillian Yuri Kumagai1,
  5. Levon Badiglian-Filho1,
  6. Graziele Bovolim2,
  7. Andrea Paiva Gadelha Guimarães3,
  8. Louise De Brot2 and
  9. Glauco Baiocchi1
    1. 1Department of Gynecologic Oncology, A.C.Camargo Cancer Center, São Paulo, Brazil
    2. 2Department of Anatomic Pathology, A.C.Camargo Cancer Center, São Paulo, Brazil
    3. 3Department of Medical Oncology, A.C.Camargo Cancer Center, São Paulo, Brazil
    1. Correspondence to Dr Glauco Baiocchi, Gynecologic Oncology, ACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil; glauco.baiocchi{at}accamargo.org.br

    Abstract

    Background Isolated positive para-aortic lymph node metastasis in endometrial cancer is an uncommon event, ranging from 1% to 3%.

    Objective Our aim was to evaluate the impact of sentinel lymph node (SLN) mapping on the risk of isolated positive para-aortic lymph node metastasis.

    Methods We retrospectively evaluated a series of 426 patients who underwent SLN mapping with at least one SLN detected from January 2013 to December 2021 (SLN group) compared with a historical series of 209 cases who underwent a systematic pelvic and para-aortic lymphadenectomy between June 2007 and April 2015 (LND group). Isolated para-aortic lymph node metastasis recurrences were included in the SLN group analysis.

    Results In the SLN group, 168 cases (39.4%) had backup systematic lymphadenectomy, and 56 (13.1%) had positive lymph nodes compared with 34 (16.3%) in LND group (p=0.18). The SLN group had higher rates of minimally invasive surgeries (p<0.001) and presence of lymphovascular space invasion (p<0.001). Moreover, SLN group had fewer other uterine risk factors, such as high-grade tumors (p<0.001), and deep myometrial invasion (p<0.001). We found that SLN mapped outside the pelvis at pre-sacral, common iliac areas, and para-aortic regions in 2.8% (n=12), 11.5% (n=49), and 1.6% (n=7) of cases, respectively. Overall, 52 (12.2%) patients had positive SLNs, and 3 (5.7%) positive SLNs were found outside the pelvis—one in the pre-sacral region, one in the common iliac area, and one in the para-aortic region. An isolated para-aortic lymph node was found in only 2 (0.5%) cases in the SLN group compared with 7 (3.3%) cases in the LND group (p=0.004).

    Conclusions SLN protocol accurately predicts lymph node status and may decrease the risk of failed identification of isolated para-aortic lymph node metastasis compared with systematic lymphadenectomy.

    • Sentinel Lymph Node
    • Lymphatic Metastasis
    • Retroperitoneal Space
    • Endometrial Neoplasms
    • Lymph Nodes

    Data availability statement

    Data are available upon reasonable request. The data and material will be available by the authors upon reasonable request.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data are available upon reasonable request. The data and material will be available by the authors upon reasonable request.

    View Full Text

    Footnotes

    • X @jaacqueline, @glaucobaiocchi

    • Contributors Study concept and design: JNM, GBa; Data acquisition: JNM, LDB, GBo, BG, LYK, CCF, GBa; Quality control of data: JNM, CCF, GBa, LDB; Data analysis and interpretation: JNM, LYK, LB-F, LDB, APGG, GBo, GBa; Statistical analysis: JNM, GBa; Manuscript preparation and editing: JNM, BG, GBa; Manuscript review: all authors; Guarantor of the manuscript: GBa.

    • Funding This study was partially sponsored by Brazilian National Research Council (CNPq) #307703/2019-3.

    • Competing interests GB reports honoraria and consulting from Astra Zeneca, GSK, and MSD.

    • Provenance and peer review Not commissioned; externally peer reviewed.